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Background: In Scotland, standard maintenance immunosuppression following kidney transplantation consists of mycophenolate (MPA), tacrolimus and prednisolone irrespective of recipient age. We analysed the tolerability of this immunosuppression regimen and the association with transplant outcomes. 
Methods: A national, multicentre retrospective analysis of patients transplanted in 2015 and 2016, comparing graft function, acute rejection, significant infection rates and immunosuppression dosing between patients aged 18-59 years (Group 1) and ≥60 years (Group 2). 
Results: Of the 490 patients, 26% were aged ≥60 years. Acute rejection (AR) rates at 1 year were 15% and 11% in Group 1 and 2 respectively. Full dose MPA was poorly tolerated with 53% in Group 1 and 77% in Group 2 requiring dose reduction or cessation. Female gender and age ≥60 years were independent predictors for MPA dose changes. One year following MPA dose reduction AR risk was low (5%) in Group 2, however those remaining on full dose MPA had a 79% increased rate of serious infections. 
Conclusion: The majority of renal transplant recipients aged ≥60 fail to tolerate full dose MPA. In this group, MPA dose reduction is associated with low rejection rates, but full dose MPA is associated with high infection rates. We suggest that a tailored approach to immunosuppression in elderly recipients incorporating lower doses of MPA may be appropriate.
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Following solid organ transplantation, establishing an immunosuppression regimen that optimizes graft function and survival whilst ensuring minimal side effects continues to be a challenge. In kidney transplantation, induction with an IL-2 receptor antagonist followed by low dose tacrolimus, mycophenolate mofetil (MMF) and prednisolone was associated with improved graft function, allograft survival and reduced acute rejection rates in the ELITE-Symphony trial1. This resulted in broad implementation of this regimen, including throughout Scotland, for the majority of transplant recipients irrespective of age. In the last 2 decades however, the amount of transplant recipients aged ≥60 in Scotland has doubled and an increased incidence of post-transplant infections, malignancies and cardiovascular events is seen in this population2,3,4,5,6. 





There are two kidney transplant units in Scotland (population 5.4 million7); in Edinburgh and Glasgow. Data was collated from paper and electronic patient records (VitalDataClient, VitalPulse limited ©, version 1.6.0.7771). All patients aged ≥18 years, who received a kidney alone or simultaneous kidney pancreas transplant in Scotland, between 1 January 2015 and 31 December 2016 entered the cohort on the day of transplantation and were followed up for a minimum of one year, until graft failure or death. 

Data collection and definitions
Baseline characteristics such as recipient age, gender, presence of diabetes mellitus, recipient and donor cytomegalovirus (CMV) serostatus, donor source (living donation or deceased donation), donor age, cause of death and cause of graft loss were retrospectively collected from clinical records. Estimated glomerular filtration rate (eGFR in ml/min/1.73m2, using Modification of Diet in Renal Disease forumla8) was collected at 1 and 2 years post-transplant. Renal biopsies, performed on indication and classified according to the Banff Classification criteria9, were reviewed by the authors and correlated with patient records reporting clinical rejection. Clinical acute rejection episodes were categorised as the sum of biopsy proven acute rejection (AR), histologically borderline AR (if treated) and presumed (empirically treated) AR. Rejection episodes in the latter two categories were only included if a deterioration in graft function prior and/or an improvement following treatment was documented. 
Any infection warranting hospital admission in the event of sepsis or necessitating immunosuppression adjustment due to graft dysfunction or biopsy-proven organ involvement in the event of CMV or BK infection was defined as ‘serious infection’. CMV infection was classified as CMV viraemia, syndrome and disease as per CMV Drug Development Forum guidelines10,11.
The magnitude of and reason for reduction of immunosuppressive drugs were documented at months 3, 6, 12 and 24 post transplantation. In the event of death or graft loss, the dosage and reason for dose reduction prior to the event were recorded. Patients with missing data on antimetabolite dosing prior to the event (N=0 at 1 year, N=4 at 2 years) were excluded for analyses of mycophenolate tolerability only.

Induction therapy and maintenance immunosuppression 
Induction therapy consisted of 2 doses of 500mg methylprednisolone in combination with either IL-2 receptor antagonist basiliximab (Simulect, Novartis Europharm Limited) 20mg intravenously on day 0 before allograft perfusion and day 4; or lymphocyte depleting agent, rabbit anti-thymocyte globulin (ATG, Genzyme) at a cumulative dose of 3mg – 6mg/kg. Local guidelines support the use of ATG in high immunological risk transplant recipients only; generally those with a donor specific antibody (DSA) present (N=23, <5%), and basiliximab in all other transplant recipients.  
Maintenance immunosuppression consisted of prednisolone 20mg from day 2 onwards, followed by a stepwise reduction to 5mg at 3 months; tacrolimus (Prograf, Astellas Pharma Europe Limited) starting at 0.1mg/kg/day in two divided doses, target trough level 5-8µg/L for standard and 8-10µg/L for high immunological risk patients; and MMF 1 gram twice a day. If gastrointestinal (GI) side effects developed, the patient was switched to enterically coated MPA at equivalent doses or administration of MMF in 4 divided doses. The dose of MPA was reduced in a stepwise fashion, switched to azathioprine and subsequently stopped if side effects persisted. 
GI side effects included diarrhoea and abdominal discomfort, in the presence of negative stool cultures and unremarkable imaging. Symptoms were only contributed to MPA if symptoms resolved following reduction of MPA or antimetabolite switch. Cytopenia was defined as WBC <3.4 and/or neutrophils <1.5 in the absence of infection. A stepwise MPA reduction was carried out until normalisation of white cell count occurred. MPA was consequently titrated up as tolerated. If BK infection developed, a stepwise reduction of immunosuppression was performed starting with MPA. In a small number of cases leflunomide was substituted for MPA. The local BK treatment protocol is summarised in Appendix 1. Patients received H2 receptor antagonists as gastric protection following transplantation.

Opportunistic infections, screening and prophylaxis
Pneumocystis Jirovecii prophylaxis with co-trimoxazole was given to all transplant recipients for a period of 3-6 months. CMV prophylaxis consisting of valganciclovir (dosing dependent on renal function with a maximum of 900 mg/day) for 6 months is given to all CMV seronegative recipients of CMV seropositive donors and to all patients receiving T-cell depleting agents. Additionally, all CMV seropositive recipients transplanted in the East of Scotland receive CMV prophylaxis. In the East of Scotland BK viraemia (BKV) screening occurs at monthly intervals for the first six months post transplantation, then 3-monthly up until 2 years  followed by 6-monthly until year 5. 

Statistical analysis
Descriptive statistics were used to summarise the baseline recipient and donor characteristics, transplant recipients were stratified by age: Group 1 (age 18-59 years) and Group 2 (age 60 years and over). Those patients who lost their graft or died were censored from analysis from the date of the event only. Patients with missing data were excluded from analysis of the variable of interest only. Cause of death was coded by ERA-EDTA cause of death codes12. 
Chi-Square testing was used to compare categorical data such as clinical acute rejection, allograft loss, death and development of post-transplant diabetes (as defined according to international consensus guidelines13) between the two age groups. Unpaired t-test was used to compare continuous normally distributed variables between the two age groups, whereas non-parametric tests were used for variables with skewed distributions.
Patient intolerance of mycophenolate was defined as any reduction of MPA or cessation of antimetabolite drugs, not caused by graft loss or patient death. The proportion of recipients requiring reduction or cessation of MPA as well as the reason for reduction were compared between age groups and gender, using Chi-Square testing. 
Univariate multiple logistic regression analysis was carried out to estimate the relative contribution (Odds Ratio (OR) and 95% CI) of the binary variables gender; recipient age; diabetes mellitus and BMI on the tolerability of mycophenolate in our cohort. Additional Log-rank testing on the former outcomes was performed for MPA tolerant and -intolerant groups; where time origin for MPA tolerant patients was defined as time of transplantation in contrast to MPA intolerant patients where time origin was defined as time from first MPA dosing change. A Cox proportionate hazard model for risk of AR was performed with age and gender as categorical, and time until MPA dose change as time-dependent covariates. Rejection-free graft survival, patient survival and time (days) until event-analysis for serious infections were analysed using Kaplan-Meier plots. Log-rank testing was performed for age Groups 1 and 2.




A total of 490 patients received a kidney transplant between 1 January 2015 and 31 December 2016 in Scotland. Twenty-seven (6%) received a simultaneous kidney/pancreas transplant and the remainder (94%) a kidney only transplant. There were 287 males (59%), and 126 recipients (26%) were 60 years or older at time of transplant (Group 2). Seventy percent of patients received a deceased donor organ [68% in Group 1 (n=246, age 18-59 years) and 77% in Group 2 (n=97, age ≥60 years), p=0.047], 18% received a pre-emptive renal transplant (19% and 15% in Group 1 and 2 respectively, p=0.358). Mean duration of follow up was 678 (±223) days; similar in the 2 age groups (Table 1).

Patient and graft survival
Unadjusted eGFR at 1 and 2 years post transplantation in both age groups is shown in Table 2. In total, 35 grafts (7%) were lost during follow up (Group 1; 7%, Group 2; 6%, p=0.688); primary non-function accounted for the loss of 12 grafts (2%). Graft survival at 1 year censored for patient death was 95% in both Groups 1 and 2. One year graft survival was 96% in those who were rejection-free and dropped to 91% following 1 or more episodes of rejection (p<0.001). 
Twenty patients (4%) died during follow up, eighteen of whom had a functioning transplant. Patients aged ≥60 had a 95% 1-year survival following transplantation, compared to 99% for patients aged <60 (p<0.001). Causes of death were cardiovascular disease in 7 patients, infection in 6 patients (4 due to Pneumocystis jiroveci), malignancy in 3 patients, withdrawal of dialysis after graft failure in 1 patient, and uncertain in 1 patient (Table 2). 

Changes to immunosuppression
At 1 year post transplantation only 40% of patients with a functioning transplant were on full maintenance dose immunosuppression consisting of MMF 1 gram twice a day (or MPA equivalent), tacrolimus and prednisolone 5mg. Early steroid or tacrolimus withdrawal was uncommon with 99% of all recipients remaining on both agents for the first year post transplantation. Mean tacrolimus level in a representative sample cohort (N=108) over the first year post-transplant was 8.1 (±1.4) ng/mL and 7.6 (±1.4) ng/mL for Group 1 and Group 2 respectively (Appendix 2 Table A2, p=0.079). 
First MPA dose adjustment was made at a median duration of 79 (IQR 21 – 178) days following transplantation (Groups 1 and 2 p=0.612). Excluding those recipients with primary graft non-function, at 1 year, ninety-two recipients (77%) in the older age group no longer received full dose MPA. This meant a dose reduction in 63 (53%), a switch to azathioprine or leflunomide in 16 (13%) and anti-metabolite cessation in 13 (11%) patients. Of the younger recipients 184 (53%) no longer received full dose MPA at 1 year; 146 patients (42%) received a reduced dose, 25 (7%) switched to azathioprine or leflunomide and 13 (4%) had all anti-proliferative agents stopped. Figure 1 illustrates that antimetabolite reduction was particularly common within the first year post-transplant and in the older recipient (MPA tolerance in Group 1 vs Groups 2; p<0.001 from 3 -24 months). 
No effect was observed between BMI or pre-transplant diabetes mellitus and MPA tolerability. Independent risk factors for failure to tolerate full dose MPA at 1 year included female gender [OR 2.5 (95% CI 1.6 – 3.9)] and age ≥60 years at time of transplant [OR 3.1 (1.8 – 5.4 95% CI)]; p≤0.001. See Figure 2 for 2 year OR. The most commonly reported reason for MPA reduction within the first year post-transplant were GI side effects in the younger recipient (18%) and infection in the older recipient [30% (p<0.001)]. Haematological side effects were given as the reason for reduction of MPA dose in 78 patients (16%), see Table 3. Intensified immunosuppression around an episode of AR triggered cytopenia in 5 patients,  none of them managed to convert back to full dose MPA during follow up. The chance of successful conversion back to full dose MPA was highest when dose reduction happened later after transplant or temporary dose reduction was related to infection. 

Effects of antimetabolite reduction on transplant outcomes
Clinical acute rejection (AR) was reported and treated in 77 patients (16%); 88% of those within the first year. Sixteen patients developed ≥2 rejection episodes. The biopsy proven rejection rate at 1 year was 9%, borderline rejection rate and presumed rejection rates were 3% and 2% respectively (see Table 2). 
Clinical AR rates at 1 year showed a decreasing trend with advancing recipient age; 15% in Group 1 and 11% in Group 2 (p=0.297). In contrast to the younger group, patients in Group 2 did not develop any AR episodes during the second year post-transplant. Median time to first AR was 73 days (IQR 7-170 days), with no difference between the age groups (p=0.155). Clinical AR rates at 1 year in MPA tolerant recipients was 13% in Group 1 and 7% in Group 2 (p=0.354), compared to 17% and 13% in MPA intolerant recipients (Group 1 vs Group 2, p=0.363). It must be noted that 44% of the rejection episodes in the intolerant group occurred prior to MPA reduction. Therefore, AR rates after MPA reduction (at a median time of 79 days post-transplant) were analysed separately. The risk of developing AR within the first year following MPA reduction was 10% in Group 1 and 5% in Group 2 (p=0.073, see Figure 3). Chronic antibody mediated rejection following immunosuppression reduction was diagnosed in 2 patients (<1%). Cox regression analysis did not identify an association between age, gender, time until MPA dose change and AR during follow up (unadjusted HR and 95% CI are presented in Appendix 3). 

Infections
A total of 212 patients developed 313 serious infections with a median time to first serious infection of 113 days post-transplant (IQR 65 – 246 days), similar in Group 1 and Group 2. Fifty-five percent of older recipients developed one or more serious infection during follow-up, 91% of these within the first year post-transplant and 62% caused by CMV, BK or PJP. Infection rates were significantly lower in younger recipients: 39% developed a serious infection, 87% of these occurred in the first year of follow-up and 58% were opportunistic. Thirty-four percent of all CMV infections were classed as CMV disease, with CMV syndrome accounting for 19% of cases. Of the BKV infections, 40% were biopsy proven BK-virus associated nephropathy. All infections caused by pneumocystis species occurred following planned cessation of co-trimoxazole. See Table 2. 
Overall risk of developing a serious infection during the first year post-transplant was 39% [36% in Group 1 and 51% in Group 2 (p=0.001; see Figure 4A)]. A 79% increased rate of infections was seen in older recipients on full dose MPA compared to those on reduced dose antimetabolite (risk of infection 70% in recipients aged ≥60 on full dose MPA vs 39% on reduced dose MPA; p=0.002, see Figure 4B). MPA reduction did not have a significant effect on infection risk in the younger age group (risk of infection 40% in recipients on full dose MPA vs 35% on reduced dose MPA; p=0.496). 




In our cohort of consecutive adult Scottish kidney transplant patients, we demonstrated that in the first year post transplantation, 60% of all recipients did not tolerate full dose MPA. The most common reasons for MPA dose modifications were infections (19% of all patients), gastrointestinal side effects (19%) and cytopenia (16%). Over three quarters (77%) of all recipients aged ≥60 received lower dose antimetabolite, however no increase in AR or graft loss were seen in this age group. 
A reduced rejection risk with age has been described in other studies following kidney, cornea, heart, lung and liver transplantation14,15. In our study MPA reduction happened at a median time of 79 days post-transplant in both age groups. Acute rejection rate one year following MPA dose reduction was 5% in older recipients, compared to 10% in the younger recipients. Chronic rejection rate at the end of follow-up was <1% in both age groups. 
Half (50%) of the older kidney transplant recipients developed at least one serious infection during the first year post-transplant; 1.5 times more often than their younger counterparts;  40% of all deaths in older recipients were infection-related compared to 25% in younger recipients. Our findings are consistent with previous literature, reporting an exponentially increased risk of infection-related death with age in transplant recipients16. Additionally, we observed a 79% increased infection risk in older recipients on full dose MPA within the first year. Given the very low acute rejection rate and reduced infectious risk after MPA dose reduction in transplant recipients aged ≥60, we suggest that tailored immunosuppression with a reduced MPA dose in this group is advisable. 
Previous research has shown that MPA dose reductions are often necessary within the first 12 months after transplant17, primarily instigated by leucopenia and GI side effects18, however the long-and short-term effects on graft function and survival is sparse. A small number of cohort studies have examined the effects of changes in immunosuppression medications and dosing post renal transplantation on graft function and these have been described in a Cochrane review by Su et al, 201119. The majority of the studies included were either low quality studies or presented combined cyclosporine and tacrolimus outcomes. The Cochrane reviewers concluded that MPA reduction or discontinuation may increase the rate of rejection and graft loss; however, the evidence was not strong and more apparent when studied in the context of cyclosporine, with tacrolimus regimens showing little difference in clinical outcomes. A more recent observational cohort study20 indicated a small increased risk of graft loss following reduction of MMF to a dose below 500mg per day or complete withdrawal in the second year post transplantation. No data were available on reason for immunosuppression reduction, graft function and acute rejection rates during the follow-up period. To the best of our knowledge no studies have reported a detailed as-treated analysis of MMF in relation to the incidence and timing of AR in two separate age groups. 
This study provides a contemporary representation of immunosuppression changes in an unselected national cohort and reflects the challenges of decision making faced by transplant physicians in the real-world. The strengths of this study include the granularity of data collected on the timing and circumstances which led to reduction of immunosuppression, the side effect profile of MPA, and the association of MPA dose reduction on patient and graft outcomes over a 2 year follow up period. Importantly, there is a consistent approach to most aspects of clinical management in Scotland employing an immunosuppression regime similar to many centres throughout Europe. Therefore, the outcomes of this study are likely to be relevant on a wider scale. Limitations of this study lie in its retrospective nature; 60% of patients did not receive the intentioned full dose immunosuppressive treatment at 1 year. However, that in itself is a notable finding and the level of detailed dosing changes collected has allowed powerful as treated analysis. In our transplant centres protocol biopsies and DSA monitoring in low-risk patients are not routinely performed and chronic antibody mediated rejection following immunosuppression reduction may consequently be underestimated in our study. 
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Figure 1:  Patient tolerance of mycophenolic acid - Antimetabolite use during the first two years post-transplant showing a gradual decrease in number of patients on full dose MPA. Comparison between age Groups 1 and 2, p<0.001 from 3 -24 months.
Figure 2: Factors predicting modification of immunosuppression at 2 years - Multiple logistic regression analysis; odds ratio (95% CI). Factors predicting dose of MPA at 2 years post-transplant. Full dose MPA compared with modified regime, which is a composite of reduced dose MPA, change of agent and antimetabolite ceased. Deceased patients and patients with a failed graft have been excluded from the analysis. Recipient age ≥60 years at time of transplant and female gender were independent risk factors predicting modified dose MPA at 2 year (OR 6.73 and 2.89 respectively). 
Figure 3: The effect of MPA reduction on Acute Rejection - Kaplan Meier hazard curve: Risk of clinical acute rejection following reduction of MPA in Group 1 (Age <60) and Group 2 (Age >=60). Log rank testing CHI2 3.21 p=0.073)
Figure 4A: Days until first serious infection - Kaplan Meier hazard curve: days until first serious infection. Risk of infection at 1 year is significantly higher in Group 2 (Age ≥60, 51%) than in Group 1 (Age <60; 36%). Log Rank testing CHI2 10.75, P=0.001. 
Figure 4B: Effect of MPA dose reduction on infection risk - Kaplan Meier hazard curve: Risk of infection stratified by age (<60 years, ≥60 years) and MPA dosing (Full dose MPA, Modified dose MPA). Time origin for patients on full dose MPA is time of transplantation, whereas time origin for patients on reduced dose MPA is the time of MPA dosing change.






Protocol for the treatment of BK infection following transplantation. Following detection and quantification of BK virus, immunosuppression is reduced starting with reduction or cessation of mycophenolate. 
Appendix 2: 
In a representative subgroup of 108 patients, mean tacrolimus level over the first year following transplantation was lower in patients aged ≥60 years, than in younger patients. No difference in mean tacrolimus level was found between those with and without acute rejection within the first year post-transplant in both groups. 
Appendix 3: 
Output of Cox regression model: no association was found between older age, female gender or time to MPA change and the risk of clinical acute rejection (CHI2 5.391, p=0.145).
Appendix 4: Visual abstract 





Table 1: Baseline characteristics 
	All patients(N=490)	Age 18 – 59(N= 364)	Age ≥60(N=126)	P-value
Age range; years, N (%)          		18 – 3940 – 4950 – 59	117 (24)109 (22)138 (28)	60 – 6970+	101 (21)26 (5)	
Gender; Male, N (%)	287 (59)	208 (57)	79 (63)	0.275
Tx Organ, N (%)KidneyKidney / Pancreas	463 (94)27 (6)	337 (93)27 (7)	126 (100)0	0.002
Live donor;  N (%)	147 (30)	118 (32)	29 (23)	0.047
Pre-emptive transplant; N (%)	81 (18)	63 (19)	18 (15)	0.358
Donor age; years (±SD)	49 (±16)	47 (±15)	57 (±15)	<0.001
Follow up duration; days,            mean (±SD)	678 (±223)	684 (±219)	661 (±231)	0.316





Table 2: Patient outcomes

	Age 18 – 59(N=364)	Age ≥60(N=126)	P-value
Graft Function			
eGFR at year 1,  mL/min/1.73m2, (±SD)	54 (19)	44 (19)	<0.001***
eGFR at year 2,  mL/min/1.73m2, (±SD)	53 (20)	45 (19)	0.001***
Rejections
Acute rejection year 1, N (%)Biopsy proven rejectionBorderline rejectionEmpirically treated rejection	54 (15)38 (10)11 (3)5 (2)	14 (11)7 (5)5 (4)2 (2)	0.124*
Late acute rejection (> 1 year), N (%)	9 (2)	0	
Graft loss and death
Graft survival year 1	95%	95%	0.726**
Patient survival year 1	99%	96%	<0.001**
Patient death during follow up, N (%)	8 (2)	12 (10)	<0.001**
Cause of death, (N)         Cardiovascular disease      InfectionMalignancyTreatment withdrawalIntra-abdominal haemorrhagePancreatitisUnknown	2211101	5420010	0.569*
Serious Infections
Infections during follow up, N (%)	143 (39)	69 (55)	0.003*
Infection rate year 1; N (%)Cytomegalovirus infectionBK virus infection Pneumocystis jiroveci infectionOther infection requiring hospital admission	125 (34)47 (13)24 (7)1 (<1)75 (21)	63 (50)22 (18)17 (14)4 (3)34 (27)	0.002*0.210*0.016*0.005*0.138*
Graft function (eGFR; estimated Glomerular Filtration Rate) at 1 and 2 years post-transplant is better in younger recipients than in older recipients (p<0.001). The majority of acute rejections happened during the first year post-transplant in Group 1 and 2 p=0.124). Time to clinical rejection and graft survival were similar in both age groups (Log rank testing, p=0.114 and p=0.868 respectively). Cause of death as per SMARRT ERA-EDTA death code groups12. Serious infection defined as any infection considered serious enough to warrant hospital admission or necessitate immunosuppression reduction.  *Chi Square testing, **Log Rank testing, *** T-test. 
Table 3: Reason for changes to MPA dosing at 1 year
	Age 18 – 59(N=347)	Age ≥60(N=119)
	Reduction of MPA	   Cessation of MPA	Reduction of MPA	Cessation of MPA
Cytopenia, N(%)	53 (15)	3 (1)	17 (14)	1 (1)
GI Side effects, N(%)	61 (18)	1 (<1)	26 (22)	1 (1)
Infection, N(%)	44 (13)	9 (2)	27 (23)	9 (7)
Malignancy, N(%)	0	0	1 (1)	2 (1)
Clinician decision, N(%)	4 (1)	0	1 (1)	0
Other, N(%)	4 (1)	0	0	0
Unclear, N(%)	5 (1)	0	7 (6)	0

Reason for reduction or cessation of MPA dosing at 1 year post transplantation stratified by age. 
GI: Gastro-Intestinal. Clinician decision: switch to Azathioprine for management of rheumatoid arthritis (1); possible contribution of breathlessness (1); reduction of MMF as deemed appropriate for low BMI (2) and low immunological risk (1). 



